| Detailed information |
|---|
| CancerLivER ID | 2031 |
| Biomarker | FGA, ITIH |
| Biomarker Name/Symbol (given in Publication) | Combination of Fibrinogen -alpha chain and ITIH |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarkers for the diagnosis of malignant liver tumors and validated on independent dataset |
| Experimental Condition | Malignant vs Benign tumor of HCC |
| Cancer type | Hepatocellular carcinoma, Cholangiocarcinoma, Hepatic adenoma |
| Regulation | Upregulated in the liver cancer cell lines |
| Level of significance | p < 0.05 |
| Source | Serum |
| PMID | 28376075 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | Total 145 patients which include 66 malignant liver tumors (34 HCC, 22 CCA, and 10 metastatic liver tumors) and 79 with benign liver tumors (34 liver cirrhosis lesions, 30 liver hemangiomas, 11 hepatic cysts, 3 hepatic adenomas, and 1 focal nodular hyperplasia)(Training Dataset :43 patients with mal |
| Sensitivity | 78.26% |
| Specificity | 88.89% |
| Accuracy | NA |
| AUC | NA |
| Disease | Human malignant and benign tumour |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |